CARY, N.C., Jan. 19, 2011 /PRNewswire/ --Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of Roger N. Hayes, Ph.D., to the role of President, Bioanalytical Operations. Dr. Hayes brings more than 15 years of scientific experience and leadership in bioanalytical testing, pharmacokinetics and pharmacodynamics, as well as extensive expertise in drug metabolism, high-throughput drug discovery and drug development.
(Photo: http://photos.prnewswire.com/prnh/20110119/PH32380 )
“We are honored to have such an accomplished scientist and business leader join us. Cetero is committed to bringing innovation to drug development, and his appointment is one additional step in allowing us to accomplish that goal. Roger has in-depth experience developing bioanalytical methods using mass spectrometry, chromatography and automation, which will allow us to enhance our analytical service offerings to our clients,” said Troy W. McCall, Ph.D., CEO of Cetero Research. “In addition, Roger’s vast knowledge of the entire drug development process will help us develop more innovative and effective solutions to help our clients improve efficiencies in their development processes.”
For the last 10 years, Dr. Hayes served as Director of Bioanalytical at Schering-Plough Research Institute, part of Merck Research Laboratories. He has also held positions with Parke-Davis Pharmaceuticals, now a division of Pfizer; Procter and Gamble; and University of Nebraska-Lincoln and spent five years as a co-administrator of a National Science Foundation mass spectrometry research facility.
“Cetero continues to look for ways to meet the evolving needs of our diverse client base,” continued Dr. McCall. “Roger’s long-standing relationships with leading technology and instrumentation manufacturers will allow Cetero to remain at the cutting edge of new technology and expand our collaborations with the industry’s leading innovators.”
Dr. Hayes commented, “I am very excited to be joining the leader in early-stage clinical research. I believe that my background, experience and leadership style will allow me to significantly contribute to the continued growth of the bioanalytical group, and certainly Cetero as a whole.”
Dr. Hayes holds three degrees, including a Ph.D. in Organic Chemistry, from the University of Adelaide in his native Australia. He has also co-authored more than 85 articles in peer-reviewed journals and given more than 20 presentations at national meetings, solidifying his status as a key thought leader in the biopharmaceutical industry. Dr. Hayes is an active member of the American Society for Mass Spectrometry and Allied Topics, the Boston Society of Advanced Therapeutics and currently serves as program chair for the 14th Annual Symposium on Chemical and Pharmaceutical Structure Analysis (CPSA 2011). He will be based in Cetero’s bioanalytical laboratory in Houston.
About Cetero Research
Cetero Research is the leading early-stage contract research organization (CRO). With nearly 30 years of experience from its founding companies, Cetero has conducted more than 20,000 clinical pharmacology studies more than any other CRO. Cetero’s proven track record allows the company to provide flexible and high-quality drug-development services. The company’s time-tested systems produce consistent and reliable data clients can trust. Cetero’s clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.
SOURCE Cetero Research
